Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3364189 | 1.00 | ALDH1A1 (0.73) | ALDH1A1GAAHPGDUSP2TP53 | |
| SCHEMBL6270443 | 0.91 | ALDH1A1 (0.66) | ALDH1A1GAAHPGDUSP2TP53 | |
| SCHEMBL6028080 | 0.89 | ALDH1A1 (0.67) | ALDH1A1GAAUSP2TP53TSHR | |
| SCHEMBL6028083 | 0.89 | ALDH1A1 (0.67) | ALDH1A1GAAUSP2TP53TSHR | |
| SCHEMBL3365348 | 0.89 | NPC1 (0.77) | ALDH1A1GAAPOLBKMT2AMEN1 | |
| SCHEMBL3366005 | 0.89 | NPC1 (0.77) | ALDH1A1GAAPOLBKMT2AMEN1 | |
| SCHEMBL3365355 | 0.89 | NPC1 (0.77) | ALDH1A1GAAPOLBKMT2AMEN1 | |
| SCHEMBL6271278 | 0.89 | NPC1 (0.77) | ALDH1A1GAAHPGDPOLBKMT2A | |
| SCHEMBL3363939 | 0.88 | GLA (0.75) | ALDH1A1HPGDUSP2TP53TSHR | |
| SCHEMBL3369373 | 0.88 | GLA (0.75) | ALDH1A1HPGDUSP2TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542969-B1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-03-03 | — | — | EP | disclosed |
| US-7122562-B2 | 4-pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20060122235-A1 | Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide | IDING HANS | 2006-06-08 | — | — | US | disclosed |
| US-7037935-B2 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1000620-B1 | Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBITORS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2005-12-07 | — | — | EP | disclosed |
| EP-1542969-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-22 | — | — | EP | disclosed |
| US-20040106650-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004026827-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | disclosed |
| US-6166036-A | Lp(a)-lowering agent and apolipoprotein (a) formation suppressing agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-1000620-A1 | Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBTORS | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-05-17 | — | — | EP | disclosed |
| EP-0393607-B1 | Phenylcarboxylic acid derivatives having a hetero ring | OTSUKA PHARMA CO LTD (JP) | 1996-02-21 | — | — | EP | disclosed |
| US-5145865-A | Fatty acid, cholesterol synthesis inhibitors; enzyme inhibitors; antilipemic agents | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1992-09-08 | — | — | US | disclosed |
| EP-0393607-A2 | Phenylcarboxylic acid derivatives having a hetero ring | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106650-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | MAOB, MAOA, COMT | ALDH1A1 556/4885GAA 80/4885HPGD 151/4885 |
| US-20060122235-A1 | Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide | MAOA, MAOB, PNPO | ALDH1A1 385/4885GAA 682/4885HPGD 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.